Interleukin-23 inhibitors may be able to reduce the risk of developing psoriatic arthritis among patients with psoriasis, ...

Interleukin 1 (IL-1 ... We also assess the rationale for clinical trials of IL-1 inhibitors aimed at preserving β-cell functional mass in patients with new-onset T1DM.

The anti-TNF era was followed by the emergence of interleukin (IL) inhibitors, with J&J’s Stelara (ustekinumab) leading the way in 2019. This therapy, initially thought to owe its efficacy to ...

Summary: Tocilizumab is a novel monoclonal antibody that competitively inhibits the binding of interleukin-6 (IL ... a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients ...

Meanwhile, Janssen’s Stelara is set to become the highest-grossing interleukin inhibitor in the market. Stelara is predicted to be the ninth best-selling drug in the world by 2025.

Department of Medicine, University of Toronto, Women's College Hospital, and co-authors have found biologics targeting ...

Scientists from F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. have patented NLRP3 inflammasome and interleukin-1β (IL1B; IL-1β) release inhibitors reported to be useful for the treatment of ...

The FDA has approved Tremfya as the “first and only” interleukin-23 inhibitor that offers both IV and fully subcutaneous ...

Tocilizumab, a novel IL-6R inhibitor, may be beneficial for the treatment of RA in patients who do not respond to methotrexate or DMARDs. A large clinical trial is needed to confirm tocilizumab's ...

Biologics work by targeting proteins that cause inflammation in ulcerative colitis. As a result, certain biologics help decrease flare-ups and complications. There are four types of biologics ...

T helper 17 (Th17) cells generate the pro-inflammatory cytokine interleukin-17 (IL17/IL17A). IL17 has been a target for a variety of therapeutic monoclonal antibodies and inhibitors to treat ...